Supplier: STILLA TECHNOLOGIES, INC.

Assay-specific crystal flex probes and primers for the detection of NRAS mutations and its positive control. The NRAS (drop-off G12-G13) Crystal Digital PCR® assay is a 10X assay designed to detect and quantify mutations in codons 12 and 13 of the NRAS gene using the ruby chip. NRAS is pivotal in regulating cell signaling pathways implicated in cancer development, notably melanoma and colorectal cancer.

Supplier: STILLA TECHNOLOGIES, INC.

The naica® mutliplex PCR MIX is a ready-to-use two-component solution specifically formulated for optimal TaqMan® fluorescent probe-based Crystal Digital PCR®.

Supplier: STILLA TECHNOLOGIES, INC.

Assay-specific Crystal Flex Probes and primers for the detection of BRAF mutations and its Positive Control. BRAF (V600, V600E) Crystal Digital PCR® Assay is a 10X assay designed to detect and quantify 1 mutation in the BRAF gene using the Ruby Chip. BRAF is pivotal in regulating cell signaling pathways implicated in cancer development, notably melanoma, colorectal cancer and thyroid cancer, through its role in the MAPK/ERK pathway. Mutations in BRAF, particularly the V600E mutation, lead to uncontrolled cell proliferation and survival.

Supplier: STILLA TECHNOLOGIES, INC.

Assay-specific Crystal Flex Probes and primers for the detection of BRAF mutations and its Positive Control. BRAF (V600, V600E, V600K) Crystal Digital PCR® Assay is a 10X assay designed to detect and quantify 2 mutations in the BRAF gene using the Ruby Chip. BRAF is pivotal in regulating cell signaling pathways implicated in cancer development, notably melanoma, colorectal cancer and thyroid cancer, through its role in the MAPK/ERK pathway. Mutations in BRAF, particularly the V600E mutation, lead to uncontrolled cell proliferation and survival.

Supplier: STILLA TECHNOLOGIES, INC.

Assay-specific Crystal Flex Probes and primers for the detection of TP53 mutations and its positive control. TP53 (drop-off V272-A276/R283-E286) Crystal Digital PCR® Assay is a 10X assay designed to detect and quantify mutations between V272-A276 or R283-E286 of the TP53 gene using the Ruby Chip. TP53 is pivotal in regulating cell divisison, thus an important tumor suppressor gene.

Supplier: STILLA TECHNOLOGIES, INC.

The Sapphire Chip features cutting-edge, patented microfluidic technology that integrates the entire digital PCR workflow into a single consumable.

Supplier: STILLA TECHNOLOGIES, INC.

Assay-specific Crystal Flex Probes and primers for the detection of PIK3CA mutations and its positive control. The PIK3CA (H1047, H1047L, H1047R) Crystal Digital PCR® Assay is a 10X assay designed to detect and quantify 2 mutation in the PIK3CA gene using the Ruby Chip. PIK3CA is essential for regulating multiple cellular processes through the PI3K/AKT/mTOR signaling pathway including cell growth, proliferation, survival, and metabolism.

Supplier: STILLA TECHNOLOGIES, INC.

Assay-specific Crystal Flex Probes and primers for the detection of PIK3CA mutations and its positive control. PIK3CA (Ref, H1047L, E542K, E545K, H1047R, N345K) Crystal Digital PCR® Assay is a 10X assay designed to detect and quantify 5 mutations in the PIK3CA gene using the Ruby Chip. PIK3CA is essential for regulating multiple cellular processes through the PI3K/AKT/mTOR signaling pathway including cell growth, proliferation, survival, and metabolism.

Supplier: STILLA TECHNOLOGIES, INC.

Assay-specific Crystal Flex Probes and primers for the detection of BRAF mutations and its Positive Control. BRAF (drop-off V600-K601) Crystal Digital PCR® Assay is a 10X assay designed to detect and quantify mutations codons V600 and K601 of the BRAF gene. BRAF is pivotal in regulating cell signaling pathways implicated in cancer development, notably melanoma, colorectal cancer and thyroid cancer, through its role in the MAPK/ERK pathway.

Supplier: STILLA TECHNOLOGIES, INC.

Assay-specific Crystal Flex Probes and primers for the detection of BRAF mutations and its Positive Control. BRAF (V600E, drop-off V600) Crystal Digital PCR® Assay is a 10X assay designed to detect and quantify mutations in codons V600-K601 plus 1 mutation in the BRAF gene. BRAF is pivotal in regulating cell signaling pathways implicated in cancer development, notably melanoma, colorectal cancer and thyroid cancer, through its role in the MAPK/ERK pathway. Mutations in BRAF, particularly the V600E mutation, lead to uncontrolled cell proliferation and survival.

Supplier: STILLA TECHNOLOGIES, INC.

Assay-specific Crystal Flex Probes and primers for the detection of TERT mutations and its Positive Control. TERT (Ref/SLC12A7/228T/C242T-C243T/C250T/TSN) Crystal Digital PCR® Assay is a 10X assay designed to detect and quantify 3 mutations in the TERT gene using the Ruby Chip. Three references are detected and used to quantify TERT gene amplification: a reference on the TERT gene, a reference on a gene located on the same chromosome as TERT (SLC12A7) and a reference on a different chromosome (TSN).

Supplier: STILLA TECHNOLOGIES, INC.

Assay-specific Crystal Flex Probes and primers for the detection of ESR1 mutations and its positive control. ESR1 (17 mutations) Crystal Digital PCR® Assay is a 10X assay designed to detect and quantify 17 mutations in the ESR1 gene using the Ruby Chip. ESR1 is pivotal in mediating resistance to endocrine therapy in metastatic hormone-positive breast cancer.

Supplier: STILLA TECHNOLOGIES, INC.

Assay-specific Crystal Flex Probes and primers for the detection of PIK3CA mutations and its positive control. The PIK3CA (H1047, H1047R) Crystal Digital PCR® Assay is a 10X assay designed to detect and quantify 1 mutation in the PIK3CA gene using the Ruby Chip. PIK3CA is essential for regulating multiple cellular processes through the PI3K/AKT/mTOR signaling pathway including cell growth, proliferation, survival, and metabolism.

Supplier: STILLA TECHNOLOGIES, INC.

Assay-specific Crystal Flex Probes and primers for the detection of NRAS mutations and its Positive Control. NRAS (G12, G12D) Crystal Digital PCR® Assay is a 10X assay designed to detect and quantify 1 mutation in the NRAS gene using the Ruby Chip. NRAS is pivotal in regulating cell signaling pathways implicated in cancer development, notably melanoma and colorectal cancer.

Supplier: STILLA TECHNOLOGIES, INC.

The Ruby Chip features cutting-edge, patented microfluidic technology that integrates the entire digital PCR workflow into a single fully automation-compatible consumable.

Supplier: STILLA TECHNOLOGIES, INC.

Assay-specific Crystal Flex Probes and primers for the detection of HPV genotypes and its positive control. HPV (ALB, HPV16/18/31/33/35) Crystal Digital PCR® Assay is a 10X assay designed to detect and quantify 5 high risk HPV genotypes for cervical cancer plus a reference gene for human DNA quantification using the Ruby Chip.

Supplier: STILLA TECHNOLOGIES, INC.

The Nio™ digital PCR instrument line offers a simple all-in-one digital PCR workflow that supports seven colors, flexible throughput of up to 768 samples per day with three configurations, continuous loading, and easy-to-use software.

Supplier: STILLA TECHNOLOGIES, INC.

Assay-specific crystal flex probes and primers for the detection of KRAS mutations and its positive control. The KRAS (G12C, drop-off G12-G13) Crystal Digital PCR® assay is a 10X assay designed to detect and quantify mutations in codons 12 and 13 plus one mutation of the KRAS gene. KRAS is pivotal in regulating cell signaling pathways implicated in cancer development, notably melanoma and colorectal cancer.

Supplier: STILLA TECHNOLOGIES, INC.

Assay-specific crystal flex probes and primers for the detection of BRAF/KRAS/NRAS mutations and its positive control. The BRAF/KRAS/NRAS Crystal Digital PCR® assay is a 10X assay designed to detect and quantify mutations in BRAF, KRAS, and NRAS genes using the ruby chip. BRAF, KRAS, and NRAS genes are pivotal in regulating cell signaling pathways implicated in cancer development.

Supplier: STILLA TECHNOLOGIES, INC.

Assay-specific Crystal Flex Probes and primers for the detection of EGFR mutations and its Positive Control. The EGFR (drop-off Del19) Crystal Digital PCR® Assay is a 10X assay designed to detect and quantify EGFR Exon 19 deletion mutations using the Ruby Chip. EGFR encodes for the epidermal growth factor receptor, a protein that plays a crucial role in cell growth, proliferation, and differentiation.

Supplier: STILLA TECHNOLOGIES, INC.

Crystal universal reporters generate fluorescent signals when activated during a Crystal Digital PCR® reaction using target-specific crystal flex probe detection chemistry.

Supplier: STILLA TECHNOLOGIES, INC.

Assay-specific Crystal Flex Probes and primers for the detection of BRCA1 Methylation and its Positive Control. The BRCA1 Methylation Crystal Digital PCR® Assay is a 10X assay designed to detect and quantify methylation of the BRCA1 promoter using the Ruby Chip. BRCA1 is crucial for maintaining genomic stability by repairing DNA damage, regulating the cell cycle, and acting as a tumor suppressor to prevent cancer.

Supplier: STILLA TECHNOLOGIES, INC.

Assay-specific Crystal Flex Probes and primers for the detection of NRAS mutations and its positive control. NRAS (Q61K, drop-off Q61) Crystal Digital PCR® Assay is a 10X assay designed to detect and quantify mutations in Q61 plus 1 mutation of the NRAS gene. NRAS is pivotal in regulating cell signaling pathways implicated in cancer development, notably melanoma and colorectal cancer.

Supplier: STILLA TECHNOLOGIES, INC.

Assay-specific Crystal Flex Probes and primers for the detection of NRAS mutations and its positive control.The NRAS (drop-off Q61) Crystal Digital PCR® Assay is a 10X assay designed to detect and quantify mutations in Q61 of the NRAS gene using the Ruby Chip. NRAS is pivotal in regulating cell signaling pathways implicated in cancer development, notably melanoma and colorectal cancer.

Supplier: STILLA TECHNOLOGIES, INC.

Assay-specific crystal flex probes and primers for the detection of KRAS mutations and its positive control. The KRAS (G12, G12C) Crystal Digital PCR® assay is a 10X assay designed to detect and quantify one mutation in the KRAS gene using the ruby chip. KRAS is pivotal in regulating cell signaling pathways implicated in cancer development, notably melanoma and colorectal cancer.

Supplier: STILLA TECHNOLOGIES, INC.

Routine Operational Qualification (OQ) procedures of the naica® system and Nio™+ can be performed using the naica® IQ/OQ Kit.

Supplier: STILLA TECHNOLOGIES, INC.

Assay-specific crystal flex probes and primers for the detection of ESRI mutations and its positive control. ESR1 (11 mutations) Crystal Digital PCR® assay is a 10X assay designed to detect and quantify 11 mutations in the ESR1 gene using the ruby chip. ESR1 is pivotal in mediating resistance to endocrine therapy in metastatic hormone-positive breast cancer.

Supplier: STILLA TECHNOLOGIES, INC.

Assay-specific Crystal Flex Probes and primers for the detection of HPV genotypes and its Positive Control. HPV (ALB, HPV16/18/31/33/35/39/45/51/52/56/58) Crystal Digital PCR® Assay is a 10X assay designed to detect and quantify 11 high risk HPV genotypes for cervical cancer plus a reference gene for human DNA quantification using the Ruby Chip.

Supplier: STILLA TECHNOLOGIES, INC.

Assay-specific Crystal Flex Probes and primers for the detection of NRAS mutations and its positive control. NRAS (G12D, drop-off G12-G13) Crystal Digital PCR® Assay is a 10X assay designed to detect and quantify mutations in G12-G13 plus 1 mutation of the NRAS gene using the Ruby Chip. NRAS is pivotal in regulating cell signaling pathways implicated in cancer development, notably melanoma and colorectal cancer.

Supplier: STILLA TECHNOLOGIES, INC.

Assay-specific crystal flex probes and primers for the detection of BRCA1/RAD51C/GSTP1 methylation and its positive control. The BRCA1/RAD51C/GSTP1 methylation Crystal Digital PCR® assay is a 10X assay designed to detect and quantify methylation of the BRCA1, RAD51C, and GSTP1 promoter using the ruby chip. Methylation of the BRCA1, RAD51C, and GSTP1 affects DNA repair mechanisms crucial for genome stability and dysregulation of detoxification pathways, both contributing to tumor initiation, progression, and drug resistance.